Spectrum Plunges After Sales Forecast Misses Estimates

Spectrum Pharmaceuticals Inc. (SPPI), a maker of cancer medicines, plunged as much as 44 percent after the drugmaker said full-year sales would fall far short of analysts’ estimates.

Shares declined to $7.95 at 5:49 p.m. New York time in extended trading, after closing at $12.43. The Henderson, Nevada-based company dropped as low as $7 after the forecast was released.

Annual 2013 revenue will be $160 million to $180 million, Spectrum said today in a statement. Analysts anticipated total revenue of $297 million, according to the average of five estimates compiled by Bloomberg. The company said sales of its top product, Fusilev, will be $80 million to $90 million.

Spectrum cited shifting ordering patterns for Fusilev, an injection known chemically as levoleucovorin, as well as the increased use of generic drugs by hospitals, for the sales forecast.

Fusilev first won FDA approval in 2008 for patients with a bone tumor called osteosarcoma. The agency two years ago cleared the drug as a treatment for patients with advanced colon cancer. The treatment generated $204 million in sales last year, Spectrum reported.

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.